13
Participants
Start Date
November 30, 2013
Primary Completion Date
July 31, 2014
Study Completion Date
July 31, 2014
Benralizumab
"Benra 30 mg q.4 Weeks is a fixed 30 mg dose of benralizumab subcutaneously on study week 0 until study week 44 inclusive.~Benra 30 mg - Placebo q.8 Weeks is a fixed 30 mg dose of benralizumab, every 4 weeks for the first 3 doses and then every 8 weeks thereafter, (placebo injections administrated at the 4 week interim visits to maintain blind). It is subcutaneously administered on study week 0 until study week 44 inclusive."
Placebo
Placebo subcutaneously on study week 0 until study week 44 inclusive.
Research Site, Birmingham
Research Site, Glendale
Research Site, San Jose
Research Site, Centennial
Research Site, Miami
Research Site, Orlando
Research Site, Pembroke Pines
Research Site, Winter Park
Research Site, Lawrenceville
Research Site, Savannah
Research Site, Bellevue
Research Site, Las Vegas
Research Site, Oklahoma City
Research Site, Pittsburgh
Research Site, Warwick
Research Site, Rock Hill
Research Site, Arlington
Research Site, Austin
Research Site, Dallas
Research Site, San Antonio
Research Site, Sugarland
Research Site, Buenos Aires
Research Site, Ciudad de Buenos Aire
Research Site, São Paulo
Research Site, Rousse
Research Site, Sofia
Research Site, Varna
Research Site, Hamburg
Research Site, Mainz
Research Site, Bydgoszcz
Research Site, Giżycko
Research Site, Lodz
Research Site, Lubin
Research Site, Ostrów Wielkopolski
Research Site, Warsaw
Research Site, Wroclaw
Research Site, Żnin
Research Site, Chelyabinsk
Research Site, Izhevsk
Research Site, Kazan'
Research Site, Moscow
Research Site, Novosibirsk
Research Site, Pyatigorsk
Research Site, Saint Petersburg
Research Site, Ulyanovsk
Research Site, Vladikavkaz
Research Site, Yekaterinburg
Lead Sponsor
AstraZeneca
INDUSTRY